NPN Compliance for Cardiovascular Supplements | Healos™
Health Canada NPN Compliance for Cardiovascular Supplements
#Pharmacists, #NPN, #Natural Health Products, #Health Canada, #Compliance, #Supplement Claims, #LNHPD
A post-cardiac patient hands you a bottle of CoQ10 and asks the question every pharmacist hears weekly: "It's Health Canada approved, so it's fine, right?"
The honest answer is "partly". The eight-digit number on the label tells you a great deal about what the product is and what it's licensed to claim. It tells you nothing about whether it belongs in this particular patient's regimen, alongside their warfarin, their statin and their DAPT.
The short answer: an NPN is an eight-digit Natural Product Number showing that Health Canada has licensed a natural health product for a specific recommended use, dose and set of cautions after reviewing safety, efficacy and quality. It confirms what is licensed. It does not guarantee the product suits a particular cardiac patient, that it is free of interactions with their medications, or that marketing beyond the licence is permitted.
简短的答案： 一位心脏术后患者递给你一瓶 CoQ10，问出药剂师每周都会听到的问题：「这是 Health Canada 批准的，所以没问题吧？」诚实的答案是「部分没问题」。
标签上的 8 位编号能告诉你很多：产品是什么、被许可宣称什么；却无法告诉你它是否适合这位患者与华法林、他汀和 DAPT 同用。NPN 表示 Health Canada 在审查安全性、有效性和质量后，针对特定推荐用途、剂量和注意事项许可了该产品。它确认「许可了什么」，不保证适合特定心脏患者、与其药物无相互作用，也不代表超出许可的营销被允许。
What an NPN actually certifies
Since the Natural Health Products Regulations (SOR/2003-196) came into force on January 1, 2004, natural health products sold in Canada have required a product licence. A licensed product carries an eight-digit NPN, or a DIN-HM for homeopathic medicines.
Behind that number sit several things a pharmacist can rely on:
The medicinal ingredients and their amounts, including the source material.
The recommended use or purpose, meaning the specific health claim Health Canada authorised.
The recommended dose, duration and route of administration.
Cautions, warnings, contraindications and known adverse reactions that must appear on the label.
Manufacturing under a site licence, with Good Manufacturing Practices requirements for the sites that make, package, label or import the product.
In other words, an NPN is strong evidence that the product in the bottle is what the label says, made to a standard, and making claims Health Canada has reviewed.
NPN 实际证明了什么： 自 2004 年 1 月 1 日《天然健康产品法规》（SOR/2003-196）生效起，在加拿大销售的天然健康产品都需要产品许可，获许可的产品带有 8 位 NPN（顺势疗法产品为 DIN-HM）。
编号背后有几项药剂师可以依赖的内容：药用成分及含量（含来源）；推荐用途，即 Health Canada 授权的具体健康宣称；推荐剂量、疗程和给药途径；标签上必须列出的注意事项、警告、禁忌和已知不良反应；在场地许可下生产，生产、包装、贴标或进口场所须符合 GMP 要求。
也就是说，NPN 有力地证明瓶中产品与标签一致、按标准生产，且其宣称经过 Health Canada 审查。
How Health Canada weighs the evidence
Health Canada takes a risk-based approach. Many common ingredients are licensed against monographs: pre-cleared documents that set out acceptable ingredients, doses, claims and cautions. A product that matches a monograph exactly can be licensed on that basis. Products with higher-risk claims, novel ingredients or doses outside a monograph need more supporting evidence, and the evidence required rises with the seriousness of the claim.
This matters for counselling. A fish oil or CoQ10 product licensed against a monograph is making a claim that sits within an established framework. A product with an unusual ingredient or an ambitious claim deserves a closer look at exactly what was licensed, and on what basis.
Health Canada 如何评估证据： Health Canada 采用基于风险的方法：很多常见成分依据「专论」（monograph）获得许可，专论预先规定了可接受的成分、剂量、宣称和注意事项，与专论完全一致的产品可据此获批；宣称风险更高、成分新颖或剂量超出专论的产品需要更多证据，宣称越严重，证据要求越高。
这对咨询很重要：依据专论许可的鱼油或 CoQ10 产品，其宣称处于既定框架内；成分特殊或宣称宏大的产品，值得仔细查看究竟许可了什么、依据是什么。
What an NPN does not tell you
This is where most patient confusion lives. An NPN does not:
Screen for interactions with a specific patient's medications. Label cautions are general. Whether CoQ10 matters for this patient's INR, or fish oil for this patient's bleeding risk on DAPT, is a professional judgement (see five drug-nutrient interactions).
Authorise claims beyond the licence. A website, social media post or sales pitch that goes further than the licensed recommended use isn't covered by the NPN.
Rank products against each other. Licensing doesn't establish that one brand is better absorbed or more effective than another.
Replace evidence for a disease outcome. A claim such as "helps support cardiovascular health" is not evidence that a product reduces heart attacks or strokes.
Confirm that the dose suits a frail, older or renally impaired patient. Magnesium in reduced kidney function is the classic example.
Stay current by itself. Licences can be amended, suspended or cancelled, so a quick database check is more reliable than the label alone.
NPN 不能告诉你什么： 患者的困惑大多在这里。NPN 不会：
① 针对特定患者的药物筛查相互作用——标签注意事项是通用的，CoQ10 是否影响这位患者的 INR、鱼油是否增加其 DAPT 下的出血风险，是专业判断；
② 授权超出许可的宣称——超出推荐用途的网站、社交媒体或销售话术不在 NPN 覆盖范围内；
③ 对产品进行排名——许可不能证明某品牌吸收更好或更有效；
④ 替代疾病结局证据——「帮助支持心血管健康」不等于证明能减少心梗或卒中；
⑤ 确认剂量适合衰弱、高龄或肾功能受损的患者——肾功能下降时的镁是典型例子；
⑥ 自动保持最新——许可可能被修改、暂停或撤销，快速查询数据库比只看标签更可靠。
How to verify an NPN in 60 seconds
The Licensed Natural Health Products Database (LNHPD) is public and searchable by NPN, product name, company or ingredient. A quick check at the counter answers most questions:
Enter the eight-digit NPN and confirm the product name and company match the bottle.
Read the recommended use. Is the patient buying it for that purpose, or for something the licence doesn't cover?
Compare the dose on the licence with how the patient is actually taking it.
Review cautions and contraindications, especially anything about anticoagulants, pregnancy, kidney disease or surgery.
Glance at the non-medicinal ingredients for allergens or, for patients on sodium or potassium limits, relevant salts.
If the number doesn't appear, or the details don't match, that is a conversation worth having before the patient continues.
60 秒核实一个 NPN： 加拿大天然健康产品许可数据库（LNHPD）公开可查，可按 NPN、产品名、公司或成分搜索。柜台上快速核查能回答大多数问题：
① 输入 8 位 NPN，确认产品名和公司与瓶身一致；
② 阅读推荐用途——患者是为此目的购买，还是用于许可不涵盖的用途？
③ 对比许可剂量与患者实际服用方式；
④ 查看注意事项和禁忌，尤其涉及抗凝药、妊娠、肾病或手术的内容；
⑤ 浏览非药用成分，留意过敏原，以及对限钠或限钾患者相关的盐类。如果查不到编号或信息不符，就值得在患者继续服用前谈一谈。
Where marketing crosses the line
An NPN licenses a claim, not a marketing campaign. Advertising for a natural health product must be consistent with its licensed recommended use, and the Food and Drugs Act (section 3 and Schedule A.1) restricts advertising to the general public that presents a product as a treatment, preventative or cure for listed serious diseases.
In cardiovascular supplements, the familiar overreaches are easy to spot once you look for them: "treats heart disease", "prevents a second heart attack", "unblocks arteries", "repairs brain cells after stroke", "replaces your statin". None of these belong on a label or in marketing for a natural health product, whatever its NPN. When patients repeat these claims at the counter, it is often the most useful moment to reset expectations: supplements can offer complementary support within their licensed use, while prescribed therapy does the heavy lifting.
营销在哪里越界： NPN 许可的是一项宣称，而不是一场营销活动。天然健康产品的广告必须与许可的推荐用途一致，《食品药品法》第 3 条和附表 A.1 限制向公众宣传产品可治疗、预防或治愈所列严重疾病。
在心血管补充剂中，常见的越界一看便知：「治疗心脏病」「预防第二次心梗」「疏通血管」「修复中风后的脑细胞」「替代他汀」——无论是否有 NPN，这些都不应出现在天然健康产品的标签或营销中。患者在柜台复述这些宣称时，往往是重设预期的最佳时机：补充剂可在许可范围内提供辅助支持，真正的重任由处方治疗承担。
What has changed recently
Two developments are worth knowing about.
Labelling. Health Canada amended natural health product labelling requirements in 2022, introducing a standardised Product Facts table and clearer allergen and contact information, with phased transition periods for existing products. Check Health Canada's current guidance for the dates that apply to a given product.
Enforcement. The Budget Implementation Act, 2023, No. 1 extended powers from the Protecting Canadians from Unsafe Drugs Act, often called Vanessa's Law, to natural health products. That gives Health Canada authority to order recalls and label changes and exposes companies to substantially higher penalties.
For pharmacists, the practical point is unchanged but reinforced: suspected adverse reactions to natural health products should be reported to Canada Vigilance, just as they would be for prescription drugs.
近期有哪些变化： 两项进展值得了解。
标签：Health Canada 于 2022 年修订天然健康产品标签要求，引入标准化的「产品信息表」（Product Facts table）和更清晰的过敏原及联系信息，现有产品有分阶段过渡期，具体日期请以 Health Canada 最新指南为准。
执法：2023 年预算实施法（第一号）将《保护加拿大人免受不安全药物法》（常称 Vanessa's Law）的权力扩展至天然健康产品，Health Canada 可下令召回和修改标签，企业面临大幅提高的处罚。
对药剂师而言，实际要点不变但更加明确：天然健康产品的疑似不良反应应向 Canada Vigilance 报告，与处方药一样。
How Healos™ applies NPN discipline
Healos™ holds itself to the same standard pharmacists apply at the counter. Its nutritional products are Health Canada NPN-licensed and described only within their authorised claims and positioned as complementary support, never as treatment, cure or prevention of any disease. Molecular hydrogen water, for example, is described as providing antioxidant support, not as a treatment for ischaemia or stroke. The H-Index is described consistently as a pre-visit communication tool, not a diagnostic test. And where an ingredient's evidence or regulatory status is still developing, Healos™ avoids making specific efficacy claims until that work is complete.
Every programme also starts with the patient's medication list, so interaction questions reach the pharmacist before a product reaches the patient.
Healos™ 如何执行 NPN 纪律： Healos™ 对自己采用药剂师在柜台上使用的同一标准：营养产品获 Health Canada NPN 许可，仅在授权宣称范围内描述，定位为辅助支持，绝不宣称治疗、治愈或预防任何疾病。例如分子氢水被描述为提供抗氧化支持，而非治疗缺血或卒中；H-Index™ 始终被描述为就诊前沟通工具，不是诊断工具；对于证据或监管状态仍在完善中的成分，在相关工作完成前不作具体功效宣称。
每个方案也都从患者用药清单开始，让相互作用问题在产品到达患者之前先到达药剂师。
The bottom line
An NPN answers "is this product what it says, and is its claim licensed?" It doesn't answer "is this right for this patient?" That second question belongs to the pharmacist, and in post-cardiac patients on antithrombotics, statins and diuretics, it's the one that matters most.
中文｜结论： NPN 回答的是「这个产品是否名副其实、其宣称是否获得许可」，不回答「它是否适合这位患者」。第二个问题属于药剂师；对于服用抗栓药、他汀和利尿剂的心脏术后患者，这恰恰是最重要的问题。
Frequently asked questions
What does an NPN number mean on a supplement? An NPN is an eight-digit Natural Product Number showing that Health Canada has licensed the product under the Natural Health Products Regulations for a specific recommended use, dose and set of cautions, after reviewing its safety, efficacy and quality.
How do I check if a supplement is licensed in Canada? Search the product's NPN in Health Canada's Licensed Natural Health Products Database (LNHPD). Confirm the product name and company, then review the licensed recommended use, dose, cautions and non-medicinal ingredients.
Can a supplement claim to treat heart disease in Canada? No. Claims must match the product's licensed recommended use, and the Food and Drugs Act restricts advertising to the public that presents products as treatments, preventatives or cures for listed serious diseases. Wording such as "helps support cardiovascular health" is only permitted where it is licensed.
Does an NPN mean a supplement is safe with my heart medications? Not necessarily. An NPN confirms general safety at the licensed dose, but it doesn't screen for interactions with your specific medications, such as warfarin, antiplatelets, statins or diuretics. Ask your pharmacist before starting any supplement.
What changed in Canadian natural health product rules recently? Health Canada introduced new labelling requirements in 2022, including a Product Facts table, with phased transitions, and in 2023 extended Vanessa's Law powers such as mandatory recalls and label changes to natural health products.
常见问题：
补充剂上的 NPN 是什么意思？表示 Health Canada 依据《天然健康产品法规》在审查安全性、有效性和质量后，针对特定推荐用途、剂量和注意事项许可了该产品。
如何查询是否获许可？在 LNHPD 数据库搜索 NPN，核对产品名、公司、推荐用途、剂量、注意事项和非药用成分。
补充剂能宣称治疗心脏病吗？不能，宣称须与许可用途一致，法律限制向公众宣传治疗、预防或治愈所列严重疾病。
有 NPN 就能和心脏药物同用吗？不一定，NPN 不针对你的具体药物筛查相互作用，开始前请咨询药剂师。
近期规则有何变化？2022 年引入含产品信息表的新标签要求（分阶段过渡），2023 年将召回、修改标签等 Vanessa's Law 权力扩展至天然健康产品。
References
Natural Health Products Regulations, SOR/2003-196 (Canada).
Health Canada. Licensed Natural Health Products Database (LNHPD).
Health Canada. Compendial monographs and the Natural Health Products Ingredients Database.
Regulations Amending the Food and Drug Regulations and the Natural Health Products Regulations (labelling). Canada Gazette, Part II. 2022.
Budget Implementation Act, 2023, No. 1 (S.C. 2023, c. 26).
Food and Drugs Act, R.S.C. 1985, c. F-27, section 3 and Schedule A.1.
Health Canada. Canada Vigilance Program: reporting adverse reactions to health products.
